化工社化工社 化学情報印刷レポート · 研究参考用
フレカイニド
(+)-N-(2-ピペリジニルメチル)-2,5-ビス(2,2,2-トリフルオロエトキシ)ベンズアミド · フレカイニド · (+)-フレカイニド · N-(2-ピペリジニルメチル)-2,5-ビス(2,2,2-トリフルオロエトキシ)ベンズアミド · N-(2-ピペリジルメチル)-2,5-ビス(2,2,2-トリフルオロエトキシ)ベンズアミド · (-)-N-(2-ピペリジニルメチル)-2,5-ビス(2,2,2-トリフルオロエトキシ)ベンズアミド · (-)-フレカイニド · 2,5-ビス(2,2,2-トリフルオロエトキシ)-N-(ピペリジン-2-イルメチル)ベンズアミド
識別子と物理属性
| CAS No. | 54143-55-4 |
|---|---|
| 分子式 | C17H20F6N2O3 |
| 平均分子量 | 414.34 g/mol |
| 単同位体質量 | 414.13781148 g/mol |
| SMILES | O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F |
| InChIKey | DJBNUMBKLMJRSA-UHFFFAOYSA-N |
| PubChem CID | 3356 |
| ChEMBL | CHEMBL652 |
| ChEBI | CHEBI:75984 |
| EC No. | 685-650-9 |
| DTXSID | DTXSID8023054 |
| 現地名 | フレカイニド |
化学・物理的性質
| XLogP | 3.8 |
|---|---|
| 極性表面積 | 59.6 |
| 水素結合供与体数 | 2 |
| 水素結合受容体数 | 10 |
| 回転可能結合数 | 7 |
| 重原子数 | 28 |
| 形式電荷 | 0 |
| 複雑度 | 500 |
| LogP（分配係数） | 3.784.6 |
| 溶解度 | 48.43.24e-02 g/Lクロロホルム（微量）、メタノール（微量） |
| 融点 | 228-229105-1070C |
| Physical Description | Solid |
| Dissociation Constants | 9.3 |
| Kovats Retention Index | 22712211.32230.5 |
| Collision Cross Section | 192.2 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)] |
| 沸点 | 434.9±45.0 °C(Predicted) |
| 密度 | 1.286±0.06 g/cm3(Predicted) |
| 引火点 | 9℃ |
| 貯蔵条件 | Keep in dark place,Inert atmosphere,Room temperature |
| 外観・状態 | 個体 |
| pKa（酸解離定数） | pKa 9.3 (Uncertain) |
| 色 | ホワイトからオフホワイト |
| BCS Class | 1 or 2 |
| 主な用途 | 臨床検査 |
| InChI | 1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26) |
| InChIKey | DJBNUMBKLMJRSA-UHFFFAOYSA-N |
| SMILES | O=C(NCC1CCCCN1)C2=CC(OCC(F)(F)F)=CC=C2OCC(F)(F)F |
| CAS データベース | 54143-55-4(CAS DataBase Reference) |
| NISTの化学物質情報 | Benzamide, n-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-(54143-55-4) |
化学的特性
White Crystalline Powder
安全性と法規制
| GHS 分類 | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]H336 (50%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposureNarcotic effects]H361 (50%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]H361d (50%): Suspected of damaging the unborn child [Warning Reproductive toxicity]P203, P261, P264, P270, P271, P280, P301+P317, P304+P340, P318, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| 規制情報 | Status: Active Update: 10-05-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/24769 |
| Hazard Classes and Categories | Acute Tox. 4 (100%)STOT SE 3 (50%)Repr. 2 (50%) |
| Treatment | Treatment of flecainide toxicity involves increasing the excretion of flecainide, blocking its effects in the heart, and (rarely) institution of cardiovascular support to avoid impending lethal arrhythmias. Modalities that have had success include administration of a beta-sympathomimetic agent, and administration of a sodium load (often in the form of hypertonic sodium bicarbonate). Placing the individual on cardiopulmonary bypass support may be necessary in order to temporarily obviate the need for a beating heart and to increase blood flow to the liver. (L1129) |
| 健康影響 | Signs of flecainide toxicity include marked prolongation of the PR interval and widening of the QRS duration on the surface ECG. There may be signs and symptoms attributable to overt heart failure secondary to sudden decreased myocardial contractility (L1129). |
| Hepatotoxicity | In clinical trials, flecainide was associated with a low rate of serum aminotransferase and alkaline phosphatase elevations. Despite wide scale use, flecainide has only rarely been linked to cases of clinically apparent liver injury. The typical presentation is with a cholestatic hepatitis arising within 1 to 6 weeks of starting flecainide. In addition, instances of acute hepatic injury arising within 1 to 3 days of starting flecainide with marked, but short lived elevations in serum aminotransferase levels and minimal increases in alkaline phosphatase have been published, but may actually represent acute worsening of congestive heart failure and ischemic hepatitis due to the proarrhythmic effects of flecainide. In all instances, the liver injury was self limited. Immunoallergic and autoimmune features were not present. |
用途
説明
From the chemical point, flecainide is an analog of procainamide, to which a 2.2.2-trifluoroethoxyl group was added at C2 and C3 of the benzene ring, and a diaminoethyl side chain is ended in the piperidine ring.
使用
Flecainide, as with other local anesthetics, is used for naturally occurring ventricular arrhythmia.